Literature DB >> 2155915

Effect of primary Epstein-Barr virus infection on human herpesvirus 6, cytomegalovirus, and measles virus immunoglobulin G titers.

A Linde1, E Fridell, H Dahl, J Andersson, P Biberfeld, B Wahren.   

Abstract

Immunoglobulin G antibody titers to human herpesvirus 6 (HHV-6), measles virus, and cytomegalovirus (CMV) were examined in serum samples from 31 patients with Epstein-Barr virus (EBV)-induced infectious mononucleosis (IM). Sera were drawn sequentially from the same patients less than or equal to 7 days until 3 years after onset of IM. In seropositive patients, there was a significant decrease with time after IM of the immunoglobulin G titers to the three viruses in the majority of patients; HHV-6 IgG titers decreased in 80%, measles virus IgG titers decreased in 75%, and CMV IgG titers decreased in 67%. Four patients contracted CMV infection during the observation period after IM. In these, HHV-6 IgG titers increased, while EBV and measles virus IgG titers remained essentially stationary. Polyclonal B-cell stimulation during IM is suggested to augment antiviral titers in general, but the increases of HHV-6 IgG titers during EBV and CMV infections may also be due to selective stimulation of memory B cells by related antigens or to reactivation of HHV-6 during infection with these herpesviruses.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2155915      PMCID: PMC269577          DOI: 10.1128/jcm.28.2.211-215.1990

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  17 in total

Review 1.  Epstein-Barr virus specific diagnostic tests in infectious mononucleosis.

Authors:  W Henle; G E Henle; C A Horwitz
Journal:  Hum Pathol       Date:  1974-09       Impact factor: 3.466

2.  An interchangeable ELISA for cytomegalovirus antigen and antibody.

Authors:  V A Sundqvist; B Wahren
Journal:  J Virol Methods       Date:  1981-04       Impact factor: 2.014

3.  The IgG subclass responses of human lymphocytes to B-cell activators.

Authors:  L Walker; G D Johnson; I C MacLennan
Journal:  Immunology       Date:  1983-10       Impact factor: 7.397

4.  A cluster of patients with a chronic mononucleosis-like syndrome. Is Epstein-Barr virus the cause?

Authors:  G P Holmes; J E Kaplan; J A Stewart; B Hunt; P F Pinsky; L B Schonberger
Journal:  JAMA       Date:  1987-05-01       Impact factor: 56.272

5.  Subclass reactivity to Epstein-Barr virus capsid antigen in primary and reactivated EBV infections.

Authors:  A Linde; J Andersson; G Lundgren; B Wahren
Journal:  J Med Virol       Date:  1987-02       Impact factor: 2.327

6.  Effect of acyclovir on infectious mononucleosis: a double-blind, placebo-controlled study.

Authors:  J Andersson; S Britton; I Ernberg; U Andersson; W Henle; B Sköldenberg; A Tisell
Journal:  J Infect Dis       Date:  1986-02       Impact factor: 5.226

7.  Humoral immune response in Epstein-Barr virus infections. I. Elevated serum concentration of the IgG1 subclass in infectious mononucleosis and nasopharyngeal carcinoma.

Authors:  W P Kaschka; R Hilgers; F Skvaril
Journal:  Clin Exp Immunol       Date:  1982-07       Impact factor: 4.330

8.  Specific and non-specific B cell activation in measles and varicella.

Authors:  P Arneborn; G Biberfeld; M Forsgren; L V von Stedingk
Journal:  Clin Exp Immunol       Date:  1983-01       Impact factor: 4.330

9.  Human herpes virus type 6 (HHV-6) and its in vitro effect on human immunodeficiency virus (HIV).

Authors:  G R Pietroboni; G B Harnett; T J Farr; M R Bucens
Journal:  J Clin Pathol       Date:  1988-12       Impact factor: 3.411

10.  Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders.

Authors:  S Z Salahuddin; D V Ablashi; P D Markham; S F Josephs; S Sturzenegger; M Kaplan; G Halligan; P Biberfeld; F Wong-Staal; B Kramarsky
Journal:  Science       Date:  1986-10-31       Impact factor: 47.728

View more
  9 in total

1.  Herpesvirus serology, aberrant specific immunoglobulin G2 and G3 subclass patterns and Gm allotypes in individuals with low levels of IgG3.

Authors:  A Linde; R Söderström; C I Smith; M Sällberg; H Dahl; R Grubb; J Björkander; L Hammarström
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

2.  Studies on the antibodies to human herpesvirus type 6 among Hungarian patients with asymptomatic HIV infection.

Authors:  C L Maródi; A Csiszár; B Sierra-Vazquez; D Di Luca; E Barabás; K Nagy; J Ongrádi
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

3.  Lack of evidence for systemic cytomegalovirus reactivation in maintenance hemodialysis patients.

Authors:  R U Pliquett; C Klein; T Grünewald; B R Ruf; J Beige
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-26       Impact factor: 3.267

Review 4.  Human herpesvirus-6 infections.

Authors:  C A Jones; D Isaacs
Journal:  Arch Dis Child       Date:  1996-02       Impact factor: 3.791

5.  Human herpesvirus 6 and chronic fatigue syndrome.

Authors:  D Eymard; F Lebel; M Miller; F Turgeon
Journal:  Can J Infect Dis       Date:  1993-07

6.  Seroprevalence of antibodies against human herpesvirus 6 in the Quebec City area.

Authors:  L Deschênes; J R Joly; M Couillard; G Richer
Journal:  Can J Infect Dis       Date:  1992-07

7.  Differentiation of bacterial and viral pneumonia in children.

Authors:  R Virkki; T Juven; H Rikalainen; E Svedström; J Mertsola; O Ruuskanen
Journal:  Thorax       Date:  2002-05       Impact factor: 9.139

8.  Does early EBV infection protect against IgE sensitization?

Authors:  Caroline Nilsson; Annika Linde; Scott M Montgomery; Liselotte Gustafsson; Per Näsman; Marita Troye Blomberg; Gunnar Lilja
Journal:  J Allergy Clin Immunol       Date:  2005-08       Impact factor: 10.793

9.  Identification of continuous human B-cell epitopes in the VP35, VP40, nucleoprotein and glycoprotein of Ebola virus.

Authors:  Pierre Becquart; Tanel Mahlakõiv; Dieudonné Nkoghe; Eric M Leroy
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.